Q2 2021 Results - Reimagining Medicine
Participants
Financial review
Conclusion
Appendix
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
Novartis pipeline in Phase 2
Oncology
Ophthalmology
References
Innovation: Clinical trials
27 lead indications
TRPV1 antagonist
Reduction of disulfide bonds
Indication(s)
Retinitis pigmentosa
Diabetic retinopathy
Chronic ocular surface pain
Presbyopia
Code
CPK850 CPK850
LKA651 LKA651
SAF312 SAF312
UNR844 UNR844
Name
Mechanism
RLBP1 AAV
EPO inhibitor
Acute GVHD,
pediatrics
Chronic GVHD,
pediatrics
Code
Name
BYL719 alpelisib
BLZ945 BLZ945
DRB436 Tafinlar® + MekinistⓇ
TabrectaⓇ
INC280
INC424
Jakavi®
LXH254
LXH254
MBG453
sabatolimab
NIR178
NIR178, spartalizumab
NIS793
NIS793
Mechanism
PI3Ka inhibitor
CSF-1R inhibitor
BRAF inhibitor + MEK inhibitor
Met inhibitor
JAK1/2 inhibitor
CRAF inhibitor
TIM3 antagonist
Ad2AR inhibitor, PD1 inhibitor
TGFB1 inhibitor
PD1 inhibitor
P-selectin inhibitor
Indication(s)
PIK3CA-related overgrowth spectrum
Solid tumors
HGG/LGG, pediatrics
Non-small cell lung cancer (Combo)
Myelofibrosis (combination)
Melanoma (combo)
Unfit acute myeloid leukaemia
Cancers
Pancreatic cancer
Metastatic melanoma (combo)
Sickle cell anaemia with crisis, pediatrics
PDR001 Spartalizumab
SEG101 Adakveo®
Immunology, Hepatology, Dermatology
Code
Name
ADPT02 ADPT02
AIN457 Cosentyx®
Mechanism
CFZ533
iscalimab
CMK389 CMK389
LJN452 tropifexor +licogliflozin
LNA043
LNA043
LOU064 remibrutinib
LRX712 LRX712
LYS006 LYS006
Indication(s)
Non-alcoholic steatohepatitis (Combos)
IL17A inhibitor
Giant cell arteritis
CD40 inhibitor
IL-18 inhibitor
FXR agonist
ANGPTL3 agonist
BTK inhibitor
Renal Tx
Atopic dermatitis
Non-alcoholic steatohepatitis (Combos)
Knee osteoarthritis
Chronic spontaneous urticaria Sjögren's
Osteoarthritis
Sjögren's
Lichen planus
Hidradenitis
Liver Tx
Respiratory Disease
Code
CMK389
CSJ117
QBW251
QMF149
Name
Mechanism
CMK389
IL-18 inhibitor
CSJ117
icenticaftor
Atectura®
TSLP inhibitor
CFTR potentiator
Combo
Cardiovascular, Renal, Metabolism
Code
Name
CFZ533 iscalimab
Mechanism
CD40 inhibitor
HSY244 HSY244
Acne
Colitis ulcerative Hidradenitis
LNP023 iptacopan
CFB inhibitor
NLRC4-GOF indications
Sjögren's
Autoimmune hepatitis
MAS825 MAS825
VAY736 ianalumab
Anti-inflammatory
BAFF-R inhibitor
Systemic lupus erythematosus
Neuroscience
Code
Name
BLZ945 BLZ945
MIJ821
MIJ821
OAV101
AVXS-101
Mechanism
CSF-1R inhibitor
NR2B inhibitor
Survival motor neuron (SMN)
gene therapy
Indication(s)
Amyotrophic lateral sclerosis
Depression
SMA IT¹)
1. Preclinical studies to address partial clinical hold completed.
50 Investor Relations | Q2 2021 Results
Global Health
Code
AFQ056
KAE609
KAF156
Name
mavoglurant
cipargamin
ganaplacide
LXE408
LXE408
Indication(s)
Pulmonary sarcoidosis
Asthma
Chronic obstructive pulmonary disease
Asthma, pediatrics
Lead indication
Bronchiectasis
Indication(s)
Lupus nephritis Type 1 diabetes mellitus
Atrial fibrillation
Membranous nephropathy Atypical haemolytic uraemic syndrome
Mechanism
mGluR5 antagonist
PfATP4 inhibitor
Indication(s)
Cocaine use disorder
Malaria, severe Malaria, uncomplicated
Malaria, uncomplicated
Protozoan inhibitor
Visceral leishmaniasis
U NOVARTIS | Reimagining MedicineView entire presentation